Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Mason

Showing results (1331-1340 of 1,358) with videos related to

Pageof 136
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|September 29, 2007
Whole-ecosystem study shows rapid fish-mercury response to changes in mercury depositionReed C Harris, John W M Rudd, Marc Amyot, et al.
Anesthesia and Analgesia|September 14, 2016
Evaluating Patient-Centered Outcomes in Clinical Trials of Procedural Sedation, Part 1 Efficacy: Sedation Consortium on Endpoints and Procedures for Treatment, Education, and Research RecommendationsMark R Williams, Denham S Ward, Douglas Carlson, et al.
The New England Journal of Medicine|June 5, 2023
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaIngo K Mellinghoff, Martin J van den Bent, Deborah T Blumenthal, et al.
Nature|December 16, 2021
Experimental evidence for recovery of mercury-contaminated fish populationsPaul J Blanchfield, John W M Rudd, Lee E Hrenchuk, et al.
Neuro-Oncology|June 4, 2011
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumorsAndrew B Lassman, Fabio M Iwamoto, Timothy F Cloughesy, et al.
Neuro-Oncology|June 5, 2012
Initial treatment patterns over time for anaplastic oligodendroglial tumorsKatherine S Panageas, Fabio M Iwamoto, Timothy F Cloughesy, et al.
Neuro-Oncology|April 17, 2018
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastomaBenjamin M Ellingson, Lauren E Abrey, Sarah J Nelson, et al.
International Journal of Radiation Biology|November 23, 2006
Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapyJames L Tatum, Gary J Kelloff, Robert J Gillies, et al.
The Lancet. Oncology|November 1, 2025
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trialTimothy F Cloughesy, Martin J van den Bent, Mehdi Touat, et al.
Neuro-Oncology|July 6, 2014
Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumorsKatherine S Panageas, Anne S Reiner, Fabio M Iwamoto, et al.
Pageof 136

Showing results (1331-1340 of 1,358) with videos related to

Sort By:
Pageof 136
Proceedings of the National Academy of Sciences of the United States of America|September 29, 2007
Whole-ecosystem study shows rapid fish-mercury response to changes in mercury depositionReed C Harris, John W M Rudd, Marc Amyot, et al.
Anesthesia and Analgesia|September 14, 2016
Evaluating Patient-Centered Outcomes in Clinical Trials of Procedural Sedation, Part 1 Efficacy: Sedation Consortium on Endpoints and Procedures for Treatment, Education, and Research RecommendationsMark R Williams, Denham S Ward, Douglas Carlson, et al.
The New England Journal of Medicine|June 5, 2023
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaIngo K Mellinghoff, Martin J van den Bent, Deborah T Blumenthal, et al.
Nature|December 16, 2021
Experimental evidence for recovery of mercury-contaminated fish populationsPaul J Blanchfield, John W M Rudd, Lee E Hrenchuk, et al.
Neuro-Oncology|June 4, 2011
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumorsAndrew B Lassman, Fabio M Iwamoto, Timothy F Cloughesy, et al.
Neuro-Oncology|June 5, 2012
Initial treatment patterns over time for anaplastic oligodendroglial tumorsKatherine S Panageas, Fabio M Iwamoto, Timothy F Cloughesy, et al.
Neuro-Oncology|April 17, 2018
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastomaBenjamin M Ellingson, Lauren E Abrey, Sarah J Nelson, et al.
International Journal of Radiation Biology|November 23, 2006
Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapyJames L Tatum, Gary J Kelloff, Robert J Gillies, et al.
The Lancet. Oncology|November 1, 2025
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trialTimothy F Cloughesy, Martin J van den Bent, Mehdi Touat, et al.
Neuro-Oncology|July 6, 2014
Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumorsKatherine S Panageas, Anne S Reiner, Fabio M Iwamoto, et al.
Pageof 136